middle.news
BLS Pharmaceuticals Posts Record $22.5m Q4 Revenue, Expands Global Manufacturing Footprint
8:57am on Thursday 30th of July, 2026 AEST
•
Pharmaceuticals
Read Story
BLS Pharmaceuticals Posts Record $22.5m Q4 Revenue, Expands Global Manufacturing Footprint
8:57am on Thursday 30th of July, 2026 AEST
Key Points
Q4 FY26 revenue hits $22.5 million, surpassing guidance
Operating cash flow reaches record $6.3 million in quarter
International GMP manufacturing platform expands in Europe, UK, LATAM
New $50 million supply agreement in Germany signed
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Bls Pharmaceuticals (ASX:BLS)
OPEN ARTICLE